Ear Care in France: New Research Report Available at Fast Market Research
In September 2012, Otipax, a common ear care product in France, was fully delisted from the official reimbursement list (listed at a 15% reimbursement rate until August 2012). This clearly confirms the ongoing impetus of the French authorities to continue de-reimbursement for benign ear care products, despite the arrival of the newly elected socialist government in May 2012, and in spite of political communication over a possible halt on the de-reimbursement spree. This was a de-reimbursement...
View full press release